Argenx SE stock (NL0010832176): shares in focus after new neuromuscular data at AAN 2026

Argenx SE draws investor attention at Euronext Amsterdam as new neuromuscular data for Vyvgart are presented at the AAN 2026 meeting, while the biotech company continues to benefit from strong U.S. sales momentum.

Argenx SE is back in the spotlight on Euronext Amsterdam after the Dutch-Belgian biotech group presented new neuromuscular data for its flagship autoimmune drug Vyvgart at the 2026 Annual Meeting of the American Academy of Neurology (AAN), underscoring its ambitions in myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP).

According to a company communication ahead of AAN 2026, Argenx highlighted additional evidence for Vyvgart Hytrulo supporting broader use across generalized MG and CIDP, including signals of early clinical improvement in treatment-naive CIDP patients, which is closely watched by specialists and investors in the United States and Europe.

The AAN 2026 presentation is important for Argenx because the United States remains the key commercial market for Vyvgart, marketed as VYVGART and VYVGART Hytrulo, while the shares are primarily listed in the Netherlands on Euronext Amsterdam under the ticker ARGX and also trade in the U.S. via Nasdaq-listed American Depositary Shares.

Argenx reported for 2025 that revenue nearly doubled year on year to more than USD 4 billion, driven mainly by strong Vyvgart uptake in generalized myasthenia gravis across the United States and other key regions, according to a report by the Belga News Agency dated 02/29/2026 citing the company.

The stock remains highly visible for European investors because Argenx is one of the larger biotech names on Euronext Amsterdam, and recent sector commentary noted that the share price had gained more than 15 percent over a 12-month period within the broader biopharmaceutical peer group tracked by MarketScreener, where Argenx appears in a sector consensus overview.

On the U.S. side, Nasdaq data show that the Argenx American Depositary Shares trade under the symbol ARGX, giving North American investors direct exposure to the Vyvgart franchise and the broader antibody pipeline.

In Germany, Argenx can be accessed via secondary trading venues such as Tradegate and Frankfurt, providing another route for retail investors who prefer to transact in euros even though the company’s primary listing venue is Euronext Amsterdam.

The latest wave of neuromuscular data at AAN 2026 comes as Argenx continues to position itself as a leader in FcRn-targeted therapies, with physicians closely monitoring whether additional indications beyond MG and CIDP can be unlocked over the medium term.

With the AAN 2026 conference taking place in the United States, Argenx’s communication is naturally geared toward the U.S. neurology community, but the read-across to investors on Euronext Amsterdam and other European venues is significant given the drug’s status as the company’s main growth engine.

The stock’s recent performance has also been supported by broader positive sentiment toward high-growth biotech names with approved commercial products, and Argenx’s growing revenue base in 2025 has been cited as an important de-risking factor in sector media coverage.

As of: 01/06/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Argenx
• Sector/industry: Biotechnology, autoimmune and neuromuscular diseases
• Headquarters/country: Rotterdam, Netherlands
• Core markets: United States, Europe, Japan
• Key revenue drivers: Vyvgart/Vyvgart Hytrulo for generalized myasthenia gravis and other autoimmune indications
• Home exchange/listing venue: Euronext Amsterdam (ARGX)
• Trading currency: EUR

Argenx SE: core business model

Argenx focuses on developing and commercializing antibody-based therapies for autoimmune and neuromuscular diseases, with the bulk of its revenue currently generated by Vyvgart and related FcRn-targeting treatments for conditions such as generalized myasthenia gravis and CIDP.

What banks and research houses say about Argenx SE

Analyst interest in Argenx remains elevated given the size of the Vyvgart opportunity and the company’s status as a leading European biotech name, with various market data services pointing to a predominantly positive stance on the stock.

Finanzen.net reported on 05/02/2026 that 10 analysts had published fresh views on Argenx over the preceding month and that all 10 recommended the stock as a buy, underlining the constructive sell-side view on the company’s growth profile and neuromuscular pipeline.

Conclusion

The new neuromuscular data for Vyvgart presented at AAN 2026 keep Argenx firmly in focus on Euronext Amsterdam and underline the strategic importance of the MG and CIDP franchises for the company’s U.S.-centric growth story.

At the same time, the 2025 revenue jump to more than USD 4 billion and the consistently positive analyst stance described by Finanzen.net illustrate how the market is increasingly treating Argenx as a mature commercial biotech rather than an early-stage developer, a perception that will be tested by future data readouts and potential label expansions.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.